What You Should Know:
- Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay.
- The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the potential of single-cell DNA and protein multiomics to identify therapeutic targets in recurrent AML.
Unearthing the Potential of Single-Cell DNA and Protein Multiomics in AML Therapy
“Through our early access program, world-leading clinicians and scientists within academia and the biopharma industry have provided robust validation showing that our scMRD AML Multiomics Assay can provide impactful insights into AML evolution and patient relapse,” said Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio. “By simultaneously interrogating DNA and protein targets at single-cell resolution and characterizing genotypic and immunophenotypic drifts over disease course, our assay not only identifies patients with recurrent AML, but potentially offers clinicians actionable treatment targets. Tapestri could transform care with comprehensive MRD detection for potentially guiding targeted treatments in AML, multiple myeloma (MM), and other blood cancers.”
As the only solution to integrate genotypic and immunophenotypic assessment, the scMRD AML Multiomics Assay targets 40 genes for single-cell DNA sequencing based on current international AML MRD guidelines, such as European LeukemiaNet, and 17-plex antibody-oligonucleotide conjugate (AOC) panel curated for key biomarkers associated with AML MRD.
Through a seamlessly integrated workflow, the assay allows clinician-researchers to:
- Distinguish true MRD from pre-leukemic or precursor clones with a limit of detection of 0.01%,
- Reveal clonal architecture (co-occurrence and zygosity of mutation) and uncover the order of acquisition of mutations (phylogeny),
- Track clonal dynamics and immunophenotypic drifts through disease course to identify therapeutic targets and therapy-resistance subclones.
A recent study published in Science Advancesand led by Wenbin Xiao, MD, PhD from the lab of world-leading leukemia specialist & physician-scientist Ross Levine, MD, Deputy Physician in Chief for Translational Research at MSK demonstrated the potential of the scMRD AML Multiomics Assay to better predict AML recurrence. The researchers found that the assay could detect clinically relevant variants missed by bulk next-generation sequencing with 0.01% limit of detection. Additionally, the researchers tapped the multiomic capabilities of the assay to illustrate the clonal architecture distinguishing leukemic clones from preleukemic clones and hematopoietic clones. Taken together, the data suggest that the scMRD AML Multiomics Assay could help identify AML relapse and has the potential to provide data-driven guidance to healthcare professionals regarding personalized treatment strategies, disease monitoring, and clinical trial stratification.
